INTRODUCTION
Daptomycin is a cyclic lipopeptide antibiotic that is approved at a dose of 4 mg/kg/day for the treatment of complicated skin and soft tissue infections (cSSTI) and at a dose of 6 mg/kg/day for the treatment of Staphylococcus aureus right-sided infective endocarditis (RIE) and bacteremia associated with cSSTI and RIE [1] .
It has a rapid, concentration-dependent bactericidal activity [2] . Daptomycin exhibits a linear pharmacokinetic profile, which is concentration proportional for doses up to 12 mg/kg/day [2] [3] [4] . As a result of its concentration-dependent bactericidal activity, higher doses ([6 mg/kg/day) have often been considered for difficult-to-treat infections [5] .
Daptomycin is a recognized alternative to vancomycin for the treatment of serious infections [6] . Optimum dosing of daptomycin for serious/deep-seated infection is not yet defined. Based on its concentration-dependent activity, higher doses of daptomycin may lead to a more rapid bacterial clearance and reduce resistance emergence [5, 7] . In infections where there is a difficulty in achieving adequate local antibiotic concentration at the infection site, or in patients with sepsis and high volumes of distribution, high-dose daptomycin may also be advantageous [4, 8] . Additionally, the intrinsic lower susceptibility of enterococci to daptomycin suggests that high doses of daptomycin may be necessary to achieve good results [9] .
Several national and international treatment guidelines include high-dose daptomycin (8-10 mg/kg/day) as a therapeutic option for difficult-to-treat infections [6, [10] [11] [12] 
METHODS

Study Design and Data Collection
This was a non-interventional, multicenter, retrospective, patient registry designed to collect real-world outcome data on patients who had received at least one dose of daptomycin for the treatment of a serious Gram-positive bacterial infection. This analysis includes all patients enrolled in the EU-CORE study who received any dose of daptomycin between 2006 and 2012: B6 mg/kg/day, [6 to \8 mg/kg/day, or C8 mg/kg/day.
Detailed EU-CORE methodology has been described elsewhere [19] . Patients who had received at least one dose of daptomycin, had a minimum of 30 days post-treatment follow-up for safety monitoring, and were not part of a controlled clinical trial, were included. A trend towards use of higher doses over time was observed, most notably in the treatment of osteomyelitis and foreign body/ prosthetic infection (Fig. 2) . Median duration of daptomycin therapy was 10 (range 1-246), 13 (range 1-300), and 14 (range 1-132) days in the B6, [6 to \8, and C8 mg/kg/day groups, respectively. The duration of daptomycin therapy was longer in patients with osteomyelitis, endocarditis, and foreign body/ prosthetic infection.
Previous and Concomitant Antibiotic Therapy
The majority of patients received other antibiotic therapy before daptomycin in the three dose groups. The most common antibiotics administered prior to daptomycin were penicillins and glycopeptides (Table 1) . Treatment failure was the most common reason for discontinuation of prior antibiotic therapy (see Appendix 1 in the supplementary material).
Most inpatients received concomitant
antibiotics with daptomycin in the three dose groups; those most commonly used for inpatients included carbapenems, penicillins, and cephalosporins.
Microbiology
Culture samples were available for 4017 (82.1%), 383 (84.7%) and 577 (89.5%) patients treated with B6, [6 to \8, and C8 mg/kg/day, respectively. Approximately, two-thirds of patients had a positive culture and S. aureus was the most commonly isolated organism (Table 2 ). Patients in high-dose groups had higher percentage of positive cultures.
Effectiveness
The overall clinical success rate (i.e., cured or improved) at the end of daptomycin therapy was 82.0% (899/1097) in the high-dose ([6 mg/ (Table 3) .
Clinical outcome was also higher in coagulase-negative staphylococcal and enterococcal infections (Fig. 3) . The clinical fasciitis, surgical/non-surgical antibiotic prophylaxis, neutropenic fever, metastatic abscess, central nervous system infection, not otherwise specified Results of both simple and multiple logistic regression analyses were consistent. As shown in Fig. 4 , the clinical success rate was greater in patients treated with daptomycin doses C8 mg/ kg/day as compared to B6 mg/kg/day, those who were treated for [28 days as compared to \14 days, and patients who underwent surgery as compared to no surgery. All the corresponding odds ratios were larger than 1.
Safety
AEs, SAEs, and 30-day overall mortality rate and mortality due to infections are presented in Table 4 . Musculoskeletal and connective tissue disorders were reported as AEs in 25 (0.4%) patients. A total of 12 cases were considered by the investigator as related to daptomycin and among them 5 were SAEs (Table 4) . Rhabdomyolysis and myalgia were the most reported AEs possibly related to daptomycin in the B6 mg/kg/day group or with higher doses of daptomycin but they were rare (0.2%). Rates of AEs leading to daptomycin discontinuation were similar between dose groups (4.0, 5.1, and 4.7% in the B6, [6 to \8, and C8 mg/kg/day groups, respectively). There were no new or unexpected safety findings at doses [6 mg/kg/day and no episodes of eosinophilic pneumonia were reported.
Discontinuation of daptomycin was observed in all patients
Increased blood creatine phosphokinase (CPK) was reported as an AE in 49 (1.0%), 9 (2.0%), and 18 (2.8%) patients in the B6, [6 to \8, and C8 mg/kg/day groups, respectively (Table 4 ). Shift to worsening CrCl from initiation to end of daptomycin therapy by daptomycin dose was 10.4% or less for all dose Effectiveness and safety of high-dose daptomycin treatment has been observed in several difficult-to-treat infections including 
